Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-1008 + Irinotecan in Metastatic Colorectal Cancer
NCT00969033Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2009
- Primary completion
- Dec 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tigatuzumab in colorectal cancer (CRC), sponsored by Daiichi Sankyo Co., Ltd.. Started Jul 2009; status: terminated.
02
Drugs
tigatuzumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00969033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00969033.